39 results about "Plasma volume" patented technology

A semiconductor wafer processing apparatus includes a first electrode exposed to a first plasma generation volume, a second electrode exposed to a second plasma generation volume, and a gas distribution unit disposed between the first and second plasma generation volumes. The first electrode is defined to transmit radiofrequency (RF) power to the first plasma generation volume, and distribute a first plasma process gas to the first plasma generation volume. The second electrode is defined to transmit RF power to the second plasma generation volume, and hold a substrate in exposure to the second plasma generation volume. The gas distribution unit includes an arrangement of through-holes defined to fluidly connect the first plasma generation volume to the second plasma generation volume. The gas distribution unit also includes an arrangement of gas supply ports defined to distribute a second plasma process gas to the second plasma generation volume.

Described herein is a method and apparatus for collecting and separating whole blood into its components, including collecting an amount of plasma and red blood cells. The collection and separation system includes a console and a disposable set. The method may include processing the blood through the centrifuge, collecting plasma, collecting red blood cells and returning red blood cells until a desired plasma volume is reached. Then a final volume of red blood cells and plasma may be collected. The disposable set may include a manifold, a CFC, and various components attached by tubing. These components may include one or more solution bags, blood product bags, bacterial filters, leukofilters, and a donor blood collection tube with access needle.

An extracorporeal circuit for removing toxins from the blood and plasma volume control in patients suffering from sepsis and renal failure. The extracorporeal circuit disclosed herein comprises a plasma filter, a toxin removal device and optionally a hemofilter that minimizes electrolyte and protein depletion from the treated plasma while effectively removing both free and protein-bound toxins. The toxin removal device comprises adsorbent materials selected from the group consisting of activated carbon, ion exchange resins and non-ionic exchange resins and the adsorbent materials are coated with albumin. Also provided are associated methods for treating patients suffering from sepsis and renal failure using the disclosed extracorporeal circuit and toxin removal device.

An extracorporeal circuit for removing toxins from the blood and plasma volume control in patients suffering from sepsis and renal failure. The extracorporeal circuit disclosed herein comprises a plasma filter, a toxin removal device and optionally a hemofilter that minimizes electrolyte and protein depletion from the treated plasma while effectively removing both free and protein-bound toxins. Also provided are associated methods for treating patients suffering from sepsis and renal failure using the disclosed extracorporeal circuit and toxin removal device.

In an extracorporeal blood treatment system, non-treated blood may be withdrawn from a patient through an arterial line connected to a first compartment of a blood treatment apparatus. The blood treatment apparatus also includes a second compartment separated from the first component by a semi-permeable membrane. Treated blood may be returned to the patient through a venous line connected to the second compartment. In order to determine blood recirculation, i.e., a mixture of treated blood and non-treated blood in the arterial line, the ultrafiltration rate of plasma water through the semi permeable membrane of the treatment apparatus may be temporarily increased or decreased, and the resulting variation of the blood concentration, i.e., of the ratio of the volume of the plasma volume to the blood volume, is determined. The extent of the mixture of the treated blood and the non-treated blood in the arterial line may then be calculated as a function of the blood flow rate in the treatment apparatus, of the amplitude of the variation of the ultrafiltration rate, and of at least two values of the blood concentration, determined before and during the variation of the ultrafiltration flow rate, respectively.

The invention provides a plasma volume reducing system and method for processing nuclear facility solid waste. The plasma volume reducing system comprises a fusion burning system and a tail gas processing system. The fusion burning system further comprises a fusion furnace and a secondary burning chamber. Low-and-intermediate level radioactive solid waste is processed through a combination mode of plasma pyrolysis fusion and secondary combustion. Tail gas generated by secondary combustion is processed in a combination mode of a half-drying-quick-cooling method, a cloth bag, a wet method and denitration. Various kinds of waste can be processed, the size of the waste is lowered to 1/6, radionuclide can be stably solidified in a solidifying body, and exhaust gas emission can reach the national standard. Comprehensively, the high volume reduction ratio and the high safety in the volume reduction technology can be achieved.

The characteristic is to use heat treating technology and plasma volume surface processing technology for CNT film cathode produced by transfer method and use plasma surface processing technology forthe CNT film cathode produced by direct growing method. The technology parameter of plasma surface process is power density 0.1 to 3 W/cubic m, the processing time is 5 to 6 minutes. H2 or hydrogen-containing compound is used. By processing according to the invention method, current density of CNT film can be increased three times, density of electric emitting point can be increased more than three times and the uniformity is increased obviously. The film cathode grown by transfer method is organic combined by two processing technologies to increase field emitting function of CNT film cathode.

Automated systems and methods for providing platelet concentrates and synthetic storage media with reduced residual plasma volumes are disclosed. The disclosed systems and methods reduce the residual volume of plasma in platelet concentrate to obtain a platelet product having a volume of plasma that is approximately 5% or less of the total platelet product volume. The disclosed systems and methods also reduce the residual volume of plasma in platelet concentrate to obtain a washed platelet product, wherein the volume of plasma in the washed platelet product is approximately 1% or less of the total washed platelet product volume. Storage media for platelets including less than approximately 10% plasma are also disclosed.

A method of generating a highly ionized plasma in a plasma chamber (2), comprises the steps of: a. providing a neutral gas to be ionized in the plasma chamber (2) at pressure below 50 Pa, b. supplying at least one high energy high power electrical pulse with power equal or larger than 100 kW and energy equal or larger than 10 J, to at least one magnetron cathode in connection with a target in the plasma chamber (2), c. producing a highly ionized plasma directly from the neutral gas in a plasma volume such that the plasma volume cross section increases during a current rise period, d. sputtering atoms from the target with the highly ionized plasma, e. ionizing at least part of the sputtered atoms.

Methods of measurement of biometric indicators in a mammalian subject are described. Biometric indicators of interest include hematocrit, plasma volume, volume of distribution, and glomerular filtration rate. The methods are especially applicable to subjects with rapid blood loss and to subjects with unstable hematocrits. Hematocrit may be measured by administering an injectate with a dynamic fluorescent marker and a static fluorescent marker, or a single static marker with two fluorescent tags, into the vascular system of the subject, and monitoring the emission intensities of the markers or fluorescent tags over a period of time. Hematocrit may then be calculated using a calibrated spectrometric analyzer by determining the raw ratio of the markers at T0, calculating the apparent hematocrit, and applying a correction factor.

Disclosed are methods for determining biometric indicators such as plasma volume, hematocrit and glomerular filtration rate, in mammalian subjects such as humans. The methods utilize a plurality of fluorescent tags having distinct fluorescent characteristics, which may be associated with a single static molecule, or wherein the static molecule is labeled with a fluorescent tag and a dynamic molecule is labeled with another fluorescent tag. One or more measurements of the intensities of the fluorescent emissions are taken subsequent to introduction of an injectate which contains the fluorescent tags, which can be taken using a probe or via a blood or plasma sample. Compositions and apparatuses for practicing the methods are also disclosed.

The present invention relates generally to measurement of body fluid volumes in an animal subject. The body fluid volumes of interest include extracellular fluid volume (ECFV), total vascular plasma volume (TVPV) and interstitial fluid volume (IFV). The methods are especially beneficial for subjects suffering from renal failure and particularly those undergoing renal dialysis. ECFV can be measured by administering a first molecule which is non-metabolized and permeable to vessel walls of the vascular system, wherein the first molecule is distributed within the total vascular space as well as the interstitial space. TVPV can be measured by administering a second molecule which is non-metabolized and impermeable to vessel walls of the vascular system, wherein the second molecule is distributed within only the vascular space. IFV can then be calculated using the equation IFV=ECFV−TVPV.

Disclosed is an oxygen-laden antishock drug, which is characterized in that the essential formulation is that: nanometer-sized oxygen-laden material and adverse-reaction-preventive component are added into hydroxyethyl starch solution whose concentration is 3-10% and whose molecular weight is 20-200kD. The invention has the advantages that the good-plasma-volume-expansion effect and the capacity to supply anoxic tissue with oxygen guarantees that the anoxic condition of different organs of human body can be quickly released and corrected and the normal physiological function can be restored gradually, so that the curing purpose can be achieved; meanwhile, unhealthy tendencies like edema of vascular endothelium and inflammatory reaction caused by ischemia can be prevented and treated by adding side-effect-preventive component of certain concentration in the oxygen-laden medical solution.

The invention discloses a platelet quantitative separation method applied to an automatic blood component separator and can provide a more optimized operation method for platelet separation. The automatic blood component separator comprises a front extrusion plate, a hanging arm, a heat sealing head and an inductive head. The separation method comprises the following steps: centrifuging series of blood collection bags containing constant plasma weight D and different red blood cell weight Gn, extruding the blood collection bags to enable a red blood cell level to reach an inductive head position, recording a front extrusion plate moving distance as an absolute distance Hn, setting extruded plasma volume D1 (D1=D-E) according to the platelet quantity demanded E, sequentially enabling the front extrusion plate to continuously extrude all the blood collection bags till the D1 volume of plasma is extruded, recording a change value relative distance delta n of each of the blood collection bags corresponding to the moving distance at the moment and enabling a corresponding relation among the blood bag specification, the absolute distance and the relative distance to form a program to guide into software for invoking during separation operation. The platelet quantitative separation method disclosed by the invention has the benefits that prepared platelet products are consistent in weight, and the platelet density difference is smaller.